×
About 57,715 results

ALLMedicine™ Multiple Sclerosis Center

Research & Reviews  18,998 results

Antigen-presenting innate lymphoid cells orchestrate neuroinflammation.
https://doi.org/10.1038/s41586-021-04136-4
Nature Grigg JB, Shanmugavadivu A et. al.

Dec 3rd, 2021 - Pro-inflammatory T cells in the central nervous system (CNS) are causally associated with multiple demyelinating and neurodegenerative diseases1-6, but the pathways that control these responses remain unclear. Here we define a population of inflam...

ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records...
https://doi.org/10.1080/21678421.2021.1946084
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Longinetti E, Sveinsson O et. al.

Dec 3rd, 2021 - Objective:To determine if inflammation in proximity of the motor unit may contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS). Methods: We identified all patients diagnosed in Sweden with concurrent ALS and multiple sclerosis (M...

Do Pilates exercises improve balance in patients with multiple sclerosis? A systematic ...
https://doi.org/10.1016/j.msard.2021.103410
Multiple Sclerosis and Related Disorders; Arik MI, Kiloatar H et. al.

Dec 3rd, 2021 - Balance problems are common in people with multiple sclerosis (MS). Pilates can also be treatment strategy for people with MS, but there is inadequate evidence to support or refute the efficacy of Pilates, especially on balance in MS patients. The...

Mitochondrial dysfunction as a trigger of programmed axon death.
https://doi.org/10.1016/j.tins.2021.10.014
Trends in Neurosciences; Merlini E, Coleman MP et. al.

Dec 3rd, 2021 - Mitochondrial failure has long been associated with programmed axon death (Wallerian degeneration, WD), a widespread and potentially preventable mechanism of axon degeneration. While early findings in axotomised axons indicated that mitochondria a...

Impact of comorbid post traumatic stress disorder on multiple sclerosis in military vet...
https://doi.org/10.1177/13524585211058361
Multiple Sclerosis (Houndmills, Basingstoke, England); Leekoff M, Culpepper W et. al.

Dec 3rd, 2021 - Very little is known regarding the impact of post traumatic stress disorder (PTSD) on the course of multiple sclerosis (MS). To explore the impact of pre-existing PTSD on MS relapses, magnetic resonance imaging (MRI) activity, and disability in a ...

see more →

Guidelines  15 results

Vision Problems in Multiple Sclerosis.
https://doi.org/10.1016/j.apmr.2020.08.003
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.

Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|

Serum neurofilament light as a biomarker in progressive multiple sclerosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538221
Neurology Kapoor R, Smith KE et. al.

Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

Practical Sleep Information for People With Multiple Sclerosis.
https://doi.org/10.1016/j.apmr.2020.03.009
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.

May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis...
https://doi.org/10.1016/j.msard.2019.04.004
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.

Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

see more →

Drugs  339 results see all →

Clinicaltrials.gov  834 results

Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis
https://clinicaltrials.gov/ct2/show/NCT01326715

Nov 25th, 2021 - Objective The original goals of this pilot study were to assess whether: (1) manganese-enhanced magnetic resonance imaging (MEMRI) using mangafodipir trisodium, a contrast agent that enters the intracellular compartment, can detect multiple sclero...

Gene Expression in Chronic Venous Leg Ulcers
https://clinicaltrials.gov/ct2/show/NCT05134597

Nov 25th, 2021 - Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries, with a prevalence ranging from 10% in adults younger than 30 years of age to nearly 80% for individuals >70 years of age. CVD clinical manifest...

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05134441

Nov 25th, 2021 - This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS....

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
https://clinicaltrials.gov/ct2/show/NCT04688788

Nov 24th, 2021 - The DanNORMS study will include patients with active multiple sclerosis aged 18-65 years. Patients will be randomized in a 2:1 ratio to either rituximab or ocrelizumab. The study duration is 24 months, and patients can continue in an extension pha...

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
https://clinicaltrials.gov/ct2/show/NCT01665144

Nov 23rd, 2021 - Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on lo...

see more →

News  2,841 results

Year in Review: Multiple Sclerosis
https://www.medpagetoday.com/neurology/multiplesclerosis/95981

Dec 2nd, 2021 - One of the first questions posed by multiple sclerosis (MS) experts in 2021 is still being asked today: How can people with MS best protect themselves against SARS-CoV-2? As early as January 13, the National MS Society advised most people with rel...

Woman with history of difficulty walking
https://www.mdedge.com/multiple-sclerosis-challenge-center/article/249222/multiple-sclerosis/woman-history-difficulty

Nov 30th, 2021 - The patient has probably transitioned to the secondary progressive form of multiple sclerosis (MS). Four phenotypes have been identified in MS, with relapsing-remitting MS (RRMS) representing the most common and secondary progressive MS (SPMS) the.

Coffee and Cognitive Decline; Head Impact Injuries; Alzheimer's Gene Therapy?
https://www.medpagetoday.com/neurology/generalneurology/95927

Nov 30th, 2021 - Higher coffee consumption was tied to slower cognitive decline and less cerebral amyloid-beta accumulation over 126 months, an Australian study showed. (Frontiers in Aging Neuroscience) Physical activity may promote synaptic and cognitive resilien...

Best of MS
https://www.mdedge.com/neurology/article/249345/multiple-sclerosis/best-ms

Nov 30th, 2021 - Good data is lacking on best first-line MS drug strategies Personalized medicine is just about the biggest buzzword in health. But neurologist Ellen M.

Diroximel Fumarate (Vumerity) Cleared for MS in Europe
https://www.medscape.com/viewarticle/963179

Nov 17th, 2021 - The European Commission (EC) has approved diroximel fumarate (Vumerity, Biogen Inc) for treatment of adults with relapsing-remitting multiple sclerosis (MS). The approval follows a thumbs-up from the Committee for Medicinal Products for Human Use ...

see more →

Patient Education  59 results see all →